Chimeric antigen receptor T cell therapy for cancer has now entered clinical trials

By Dartmouth Norris Cancer Research Center laboratory developed cancer Sentman chimeric antigen receptor (Chimeric antigen receptor, CAR) T cells is currently undergoing Phase I clinical trials, researchers, Professor Charles Sentman that we developed CAR therapy in the treatment of many different cancers have a wide range of application, later studies have shown, CAR therapy can not only eliminate tumors in experimental animals organism, and effectively inhibit the recurrence of cancer.

CN-CS1 is the first clinical trials of a first therapy, it is possible to raise an autologous NKG2D cell receptor CAR T cell therapy, NKG2D as a natural killer cell receptors, targeting most of Rat Kidney injury molecule 1 ELISA Kit http://www.cusabio.com/ELISA_Kit-82149/ which may in the presence of ligands, including blood cancer and solid tumors; current clinical trial investigators conducted in hematological cancers, such as leukemia and myeloma, the current value is widely used in clinical trials in the treatment so as to have more cancer research reaching prospects.

With a new generation of platform technologies, many related to other therapies currently undergoing preclinical development phase, the next-generation platform technology developed in the laboratory from Sentman CAR T cells can be with another innovative TCR- inhibitory molecules (TIMs ) combined; TIMs CAR therapy can be used to perform T cell research healthy donors, thus after avoid graft versus host reactions (Graft-Versus-Host-Disease, GVHD). If successful, TIM / CAR therapy therapy will minimize the time spent, and decreased patient costs.

Finally, the researchers Sentman said, we are very pleased to be the opportunity we have developed a new type of therapy used in clinical treatment, it has a very important significance for the development of novel cancer immunotherapy, the potential of cell therapy CAR will also improve patient health tremendous hope.